Jeff A. Sloan

Jeff A. Sloan

Auto-generated profile, based on publicly available information

Jeff A. Sloan

Mayo Clinic, Rochester, MN

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2014 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
JDJuan Pablo Domecq
Juan Pablo Domecq
GPGabriela Prutsky
Gabriela Prutsky
TETarig Elraiyah
Tarig Elraiyah
ZWZhen Wang
Zhen Wang
MNMohammed Nabhan
Mohammed Nabhan
MMMohammad Hassan Murad
Mohammad Hassan Murad
A compelling ethical rationale supports patient engagement in healthcare research. It is also assumed that patient engagement will lead to research findings that are more pertinent to patients’ concerns and dilemmas. However; it is unclear how to best conduct this process. In this systematic review we aimed to answer 4 key questions: what are the best ways to identify patient representatives? How to engage them in designing and conducting research? What are the observed benefits of patient engagement? What are the harms and barriers of patient engagement? We searched MEDLINE, EMBASE, PsycInfo, Cochrane, EBSCO, CINAHL, SCOPUS, Web of Science, Business Search Premier, Academic Search Premier and Google Scholar. Included studies were published in English, of any size or design that described engaging patients or their surrogates in research design. We conducted an environmental scan of the grey literature and consulted with experts and patients. Data were analyzed using a non-quantitative, meta-narrative approach. We included 142 studies that described a spectrum of engagement. In general, engagement was feasible in most settings and most commonly done in the beginning of research (agenda setting and protocol development) and less commonly during the execution and translation of research. We found no comparative analytic studies to recommend a particular method. Patient engagement increased study enrollment rates and aided researchers in securing funding, designing study protocols and choosing relevant outcomes. The most commonly cited challenges were related to logistics (extra time and funding needed for engagement) and to an overarching worry of a tokenistic engagement. Patient engagement in healthcare research is likely feasible in many settings. However, this engagement comes at a cost and can become tokenistic. Research dedicated to identifying the best methods to achieve engagement is lacking and clearly needed.

1 November 2015 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
ADAmylou C. Dueck
Amylou C. Dueck
TMTito R. Mendoza
Tito R. Mendoza
SMSandra A Mitchell
Sandra A Mitchell
BRBryce B Reeve
Bryce B Reeve
KCKathleen M. Castro
Kathleen M. Castro
FGfor the National Cancer Institute PRO-CTCAE Study Group
for the National Cancer Institute PRO-CTCAE Study Group
In cancer clinical trials, adverse events (AEs) are collected and reported using the US National Cancer Institute’s (NCI’s) Common Terminology Criteria for Adverse Events (CTCAE).1 The CTCAE is a library of items representing 790 discrete AEs, each graded using an ordinal severity scale.2 Approximately 10% of AEs in the CTCAE are symptoms (eg, nausea, sensory neuropathy), which in trials have historically been reported by clinical investigators.3 However, there is empirical evidence that collection of this information directly from patients improves the precision and reliability of symptomatic AE detection in trials4-9and is feasible.10,11 Moreover, there is substantial evidence that clinical investigators may miss up to half of patients’ symptomatic AEs.5,6,12,13

27 September 2006 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
DRDennis A Revicki
Dennis A Revicki
DCDavid Cella
David Cella
RHRon D. Hays
Ron D. Hays
JSJeff A Sloan
Jeff A Sloan
WLWilliam R Lenderking
William R Lenderking
NANeil K Aaronson
Neil K Aaronson
Patient reported outcomes provide the patient's perspective on the effectiveness of treatment. The draft Food and Drug Administration guidance on patient reported outcomes for labeling and promotional claims raises a number of method and measurement issues that require further clarification, including methods of determining responsiveness and minimal important differences. For clinical trials, instruments need to be based on a clear conceptual framework, have evidence supporting content validity and acceptable psychometric qualities. The measures must also have evidence documenting responsiveness and interpretation guidelines (i.e., minimal important difference) to be most useful as effectiveness endpoints in clinical trials. The recommended approach is to estimate the minimal important difference based on several anchor-based methods, with relevant clinical or patient-based indicators, and to examine various distribution-based estimates (i.e., effect size, standardized response mean, standard error of measurement) as supportive information, and then to triangulate on a single value or small range of values for the MID. Confidence in a specific MID value evolves over time and is confirmed by additional research evidence, including clinical trial experience. The MID may vary by population and context, and no one MID will be valid for all study applications involving a PRO instrument. Responsiveness and MID must be demonstrated and documented for the particular study population, and these measurement characteristics are needed for PRO labeling and promotional claims.

1 January 2003 in Drug Information Journal
Verified
Journal Article
Closed access
JSJeff Sloan
Jeff Sloan
TSTara Symonds
Tara Symonds
DVDelfino Vargas-Chanes
Delfino Vargas-Chanes
BFBrooke Fridley
Brooke Fridley

1 May 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JSJeff A. Sloan
Jeff A. Sloan
XZXinghua Zhao
Xinghua Zhao
PNPaul J. Novotny
Paul J. Novotny
JWJason Wampfler
Jason Wampfler
YGYolanda Garces
Yolanda Garces
PYPing Yang
Ping Yang
Purpose: Evidence has suggested a clinically meaningful relationship between self-reported quality of life (QOL) of a patient with cancer at the time of receiving a cancer diagnosis and overall survival (OS). This study evaluated the prognostic value of QOL assessments with regard to OS in a large cohort of patients with lung cancer. Patients and Methods: A total of 2,442 patients with non–small-cell lung cancer were observed between 1997 and 2007 and completed a single-item measure of overall QOL within the first 6 months of receiving a lung cancer diagnosis; these were dichotomized using an a priori definition of a clinically deficient score (CDS; ≤ 50 v > 50). Kaplan-Meier estimates and Cox models were used to evaluate the prognostic importance of QOL on OS alone and in the presence of covariates. Logistic regression modeling was used to identify which clinical and patient characteristics were related to a clinically meaningful deficit in QOL. Results: QOL deficits at time of lung cancer diagnosis were significantly associated with OS (hazard ratio [HR], 1.55; P < .001), as were performance status, older age, smoking history, male sex, treatment factors, and stage of disease. The median survival for patients with CDS QOL was 1.6 years versus 5.6 years for patients with non-CDS QOL. After controlling for all these covariates, the indication of a clinically deficient baseline QOL still contributed significantly to the prediction of patient survival (HR, 0.67; P < .001). Conclusion: Overall QOL measured by a simple single item at the time of lung cancer diagnosis is a significant and independent prognostic factor for survival in patients with lung cancer.

1 January 2005 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Closed access
JSJeff A. Sloan
Jeff A. Sloan
(2005). Assessing the Minimally Clinically Significant Difference: Scientific Considerations, Challenges and Solutions. COPD: Journal of Chronic Obstructive Pulmonary Disease: Vol. 2, No. 1, pp. 57-62.